ATLANTA, August 28, 2026, 14:15 EDT
- Femasys shares were up 15.05% at $3.21 as of 13:52 EDT.
- FemaSeed and its companion diagnostics will be available at UNC Health OB/GYN practices.
- Sales for the second quarter declined 18.9% to $331,827; commercial terms were not revealed.
Femasys (NASDAQ: FEMY) stock climbed 15.05% on Friday following an agreement with UNC Health to roll out the FemaSeed fertility portfolio in its OB/GYN clinics.
The change boosted equity value by approximately $1.41 million, a sum more than four times higher than Femasys’ second-quarter revenue.
The collaboration brings FemaSeed Complete, FemVue, and SpermVue to North Carolina’s academic health system statewide. Femasys did not reveal information on pricing, number of locations, or revenue obligations.
The deployment equips OB/GYNs with resources to assess and care for patients ahead of referring them to specialists. This move aligns directly with Femasys’ commercial strategy, the company said in its August 26 announcement.
At 13:52 EDT, shares were changing hands at $3.21, close to their session peak of $3.33. Trading volume was approximately 403,000 shares.
| Investor measure | Latest reading | Interpretation |
|---|---|---|
| Share price | $3.21; up 15.05% | Market cap rises roughly $1.41 million |
| Q2 sales | $331,827; down 18.9% | Sales footprint remains limited |
| Q2 net loss | $4.47 million | Spending for launch outpaces income |
| FemaSeed trial | 24% pregnancy rate by subject | Evidence backs use as primary option |
| Private placement | $30 million gross proceeds | Provides capital for U.S. market rollout |
FemaSeed deposits sperm directly into the fallopian tube instead of the uterus. The device received FDA clearance in 2023.
Among women in the pivotal study’s severe male-factor group, 24% of 42 participants achieved pregnancy. Across 62 treatment cycles, the pregnancy rate stood at 16%, compared with a 6.7% historical rate for IUI, company-reported trial data show. For details, see the company announcement.
The findings serve as a clinical sales tool, but do not determine the speed at which community OB/GYN practices will implement the procedure.
Femasys posted sales of $331,827 for the second quarter, representing an 18.9% decline from the previous year. The company reported a modest reduction in net loss to $4.47 million, as stated in the quarterly release.
As of June 30, cash stood at $1.4 million. A later private placement generated $30 million in gross proceeds, potentially increasing to $90 million if all warrants are exercised.
The funding is substantial compared to existing sales. The immediate focus moves from securing financial survival to achieving commercial traction.
Risks: Details of the partnership agreement have not been made public. Uptake could be gradual, reimbursement policies differ, and limited revenue contributes to fluctuations in quarterly earnings.
Friday’s rally reflects the benefits of tapping into a reliable health network. Maintaining momentum will depend on securing orders, recurring procedures, and clear evidence of revenue growth.
Related articles: Biotechnology
